Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches
Background Glioblastoma, or glioblastoma multiforme (GBM), remains a fatal cancer type
despite the remarkable progress in understanding the genesis and propagation of the tumor …
despite the remarkable progress in understanding the genesis and propagation of the tumor …
Lipid‐based nanocarriers for the treatment of glioblastoma
N Iturrioz-Rodríguez, R Bertorelli… - Advanced nanobiomed …, 2021 - Wiley Online Library
Glioblastoma multiforme (GBM) is the most common and malignant neoplasia having origin
in the brain. The current treatments involve surgery, radiotherapy, and chemotherapy, being …
in the brain. The current treatments involve surgery, radiotherapy, and chemotherapy, being …
[HTML][HTML] Drug delivery of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to target brain tumors
S Mehrdadi - Advanced Pharmaceutical Bulletin, 2023 - ncbi.nlm.nih.gov
Brain, predisposed to local and metastasized tumors, has always been the focus of
oncological studies. Glioblastoma multiforme (GBM), the most common invasive primary …
oncological studies. Glioblastoma multiforme (GBM), the most common invasive primary …
Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles
A Miranda, MJ Blanco-Prieto, J Sousa, A Pais… - International journal of …, 2017 - Elsevier
Tailored nanocarriers have gained huge research focus for brain drug delivery, aimed at
combating several neuro-oncological conditions, such as the glioblastoma multiforme …
combating several neuro-oncological conditions, such as the glioblastoma multiforme …
Combination drug loaded lipid-based nanocarriers as treatment entity for battling glioblastoma multiforme
Glioblastoma multiform (GBM) is the most lethal form of brain cancer pigeonholed by a high
rate of reoccurrence and poor diagnosis. Among all treatment strategies available …
rate of reoccurrence and poor diagnosis. Among all treatment strategies available …
Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme
R Jnaidi, AJ Almeida, LM Gonçalves - Pharmaceutics, 2020 - mdpi.com
Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In
fact, tumor recurrence usually appears a few months after surgical resection and …
fact, tumor recurrence usually appears a few months after surgical resection and …
Lipid based nanoparticles: Current strategies for brain tumor targeting
BC Mohanta, NN Palei, V Surendran… - Current …, 2019 - ingentaconnect.com
Brain tumors arise from an uncontrolled proliferation of neural tissue cells or supportive glial
tissue cells within the brain. The diagnosis and therapy of brain tumor is an extremely …
tissue cells within the brain. The diagnosis and therapy of brain tumor is an extremely …
Glioblastoma multiforme and lipid nanocapsules: a review
J Aparicio-Blanco… - Journal of biomedical …, 2015 - ingentaconnect.com
Epidemiological data on central nervous system disorders call for a focus on the major
hindrance to brain drug delivery, blood-central nervous system barriers. Otherwise, there is …
hindrance to brain drug delivery, blood-central nervous system barriers. Otherwise, there is …
Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles
A Anand, A Sugumaran… - IET …, 2019 - Wiley Online Library
A brain tumour is amongst most devastating and challenging condition to overcome with
suitable treatment as the drug has to cross the blood–brain barrier (BBB) with several …
suitable treatment as the drug has to cross the blood–brain barrier (BBB) with several …
Recent advances in the use of lipid-based nanoparticles against glioblastoma multiforme
B Ortega-Berlanga, C Gonzalez… - Archivum Immunologiae et …, 2021 - Springer
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults.
Although the overall incidence is less than 10 per 100,000 individuals, its poor prognosis …
Although the overall incidence is less than 10 per 100,000 individuals, its poor prognosis …